The COVID-19 global pandemic has fundamentally altered how equity financing and M&A transactions are being structured by and for life sciences issuers.

Join this panel of life sciences industry experts, from investment bankers and advisers to equity capital market participants and companies exploring M&A transactions, to learn about what trends and opportunities they see as the “new normal” continues to evolve.